1,611 reports of this reaction
1.5% of all DABIGATRAN ETEXILATE reports
#16 most reported adverse reaction
DYSPEPSIA is the #16 most commonly reported adverse reaction for DABIGATRAN ETEXILATE, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 1,611 FDA adverse event reports linking DABIGATRAN ETEXILATE to DYSPEPSIA. This represents approximately 1.5% of all 111,048 adverse event reports for this drug.
Patients taking DABIGATRAN ETEXILATE who experience dyspepsia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPEPSIA is a less commonly reported adverse event for DABIGATRAN ETEXILATE, but still significant enough to appear in the safety profile.
In addition to dyspepsia, the following adverse reactions have been reported for DABIGATRAN ETEXILATE:
The following drugs have also been linked to dyspepsia in FDA adverse event reports:
DYSPEPSIA has been reported as an adverse event in 1,611 FDA reports for DABIGATRAN ETEXILATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPEPSIA accounts for approximately 1.5% of all adverse event reports for DABIGATRAN ETEXILATE, making it a notable side effect.
If you experience dyspepsia while taking DABIGATRAN ETEXILATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.